FI932282A0 - Protein C-derivat - Google Patents

Protein C-derivat

Info

Publication number
FI932282A0
FI932282A0 FI932282A FI932282A FI932282A0 FI 932282 A0 FI932282 A0 FI 932282A0 FI 932282 A FI932282 A FI 932282A FI 932282 A FI932282 A FI 932282A FI 932282 A0 FI932282 A0 FI 932282A0
Authority
FI
Finland
Prior art keywords
derivatives
human protein
protein
producing
high activity
Prior art date
Application number
FI932282A
Other languages
English (en)
Other versions
FI932282A (fi
Inventor
Bruce Edward Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI932282A0 publication Critical patent/FI932282A0/fi
Publication of FI932282A publication Critical patent/FI932282A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI932282A 1992-05-21 1993-05-19 Protein c-derivat FI932282A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (2)

Publication Number Publication Date
FI932282A0 true FI932282A0 (fi) 1993-05-19
FI932282A FI932282A (fi) 1993-11-22

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932282A FI932282A (fi) 1992-05-21 1993-05-19 Protein c-derivat

Country Status (23)

Country Link
US (1) US5453373A (fi)
EP (1) EP0575054B1 (fi)
JP (1) JP3564150B2 (fi)
KR (1) KR100291529B1 (fi)
CN (1) CN1080658A (fi)
AT (1) ATE286121T1 (fi)
AU (1) AU661901B2 (fi)
BR (1) BR9301944A (fi)
CA (1) CA2096604C (fi)
CZ (1) CZ286016B6 (fi)
DE (1) DE69333727T2 (fi)
DK (1) DK0575054T3 (fi)
ES (1) ES2233925T3 (fi)
FI (1) FI932282A (fi)
HU (1) HU218408B (fi)
IL (1) IL105757A0 (fi)
MX (1) MX9302917A (fi)
MY (1) MY110664A (fi)
NO (1) NO311299B1 (fi)
NZ (1) NZ247651A (fi)
PH (1) PH29911A (fi)
PT (1) PT575054E (fi)
RU (1) RU2122004C1 (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
BR9809304B1 (pt) 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU5131699A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Cryogranulation of activated protein c
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
IL142255A0 (en) 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2001036462A2 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CN100392079C (zh) * 2000-10-18 2008-06-04 马克西根公司 蛋白c或活化的蛋白c-样分子
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
US20100184672A1 (en) * 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN102325880B (zh) 2008-12-19 2014-10-01 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
HU9301461D0 (en) 1993-09-28
AU3869993A (en) 1993-11-25
NO931840L (no) 1993-11-22
US5453373A (en) 1995-09-26
EP0575054A2 (en) 1993-12-22
EP0575054B1 (en) 2004-12-29
KR930023370A (ko) 1993-12-18
NO931840D0 (no) 1993-05-19
CA2096604C (en) 2003-12-16
IL105757A0 (en) 1993-09-22
NO311299B1 (no) 2001-11-12
KR100291529B1 (ko) 2001-06-01
CZ94893A3 (en) 1994-01-19
CN1080658A (zh) 1994-01-12
DE69333727D1 (de) 2005-02-03
HU218408B (hu) 2000-08-28
FI932282A (fi) 1993-11-22
CZ286016B6 (cs) 1999-12-15
AU661901B2 (en) 1995-08-10
MX9302917A (es) 1993-11-01
JPH0680698A (ja) 1994-03-22
JP3564150B2 (ja) 2004-09-08
NZ247651A (en) 1995-03-28
ES2233925T3 (es) 2005-06-16
PT575054E (pt) 2005-03-31
HUT69615A (en) 1995-09-28
DE69333727T2 (de) 2005-12-15
PH29911A (en) 1996-09-16
ATE286121T1 (de) 2005-01-15
DK0575054T3 (da) 2005-04-25
RU2122004C1 (ru) 1998-11-20
CA2096604A1 (en) 1993-11-22
BR9301944A (pt) 1993-11-30
MY110664A (en) 1999-01-30
EP0575054A3 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
FI932282A0 (fi) Protein C-derivat
NO900770L (no) Produksjon av glykoseoksidase i rekombinante systemer.
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
YU31891A (sh) Vektori i jedinjenja za ekspresiju mutanata glikozilovanja humanog proteina c
TR26073A (tr) Bacillus thuringiensis jenleri,toksinleri ve insektisid olarak kullanimlari.
ATE59777T1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE68924022D1 (de) Protein mit hemmender Aktivität gegenüber menschlichem Plasmin.
DE3862073D1 (de) Tetramethyl-cis-diaza-bicyclo(4.2.0.)oktan-3,5-dion-derivate mit differentiationsinduzierender aktivitaet.
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.
FI950779A0 (fi) Homepromoottorit, jotka ovat aktiivisia glukoosin läsnäollessa
ATE92110T1 (de) Menschliches interleukin-4, expressionsvektoren dafuer und diese enthaltende transformanten.